As a psychedelic therapy developer, Compass Pathways (NASDAQ: CMPS) is on the cutting edge of innovation in treating mood disorders. That makes it an exciting, if quite risky, investment. But a lot of that risk burden could be alleviated soon, thanks to a pair of upcoming catalysts. If that happens, ...
motleyfoolusx:cmps